Decursin

Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities^[1][2][3][4]. In Vitro: Decursin (0, 25, 50, 100 µM; 24, 28, 72, 96 h) inhibits cell growth in a dose- and time- dependent manner in DU145 cells^[1].
Decursin (0, 25, 50, 100 µM; 24, 28, 72, 96 h) induces apoptosis and cell cycle arrest at G1 phase in DU145 cells, G1, S as well as G2-M arrests in PC-3 cells^[1].
Decursin (0, 25, 50, 100 µM; 24, 48 h) decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h in DU145 cells^[1].
Decursin (0, 5, 20, 100 µM; 7 days) inhibits the proliferation and differentiation ability of AC133+ cells^[2].
Decursin (0, 5, 20, 100 µM) inhibits SDF-1a-induced activation of Akt, ERK1/2, and eNOS in a dose-dependent manner^[2]. In Vivo: Decursin (4 mg/kg; s.c.; daily for 4 weeks) shows anti-tumor activity in mouse^[2].
Decursin (50 mg/kg; intrathecal injection; three times at 2-day intervals, for 6 days) shows analgesic ability in paclitaxel-induced peripheral neuropathy in mouse^[3].